定量冷冻喷雾治疗慢性支气管炎:一项机制性随机对照研究
该研究为1:1随机、盲法、假手术对照的机制性试验,纳入慢阻肺合并慢性支气管炎患者,评估定量冷冻喷雾对杯状细胞密度的影响。结果显示治疗6个月未降低杯状细胞密度,但圣乔治呼吸问卷总分改善且呼气低衰减区减少,提示症状与影像学气体陷闭指标获益。
要点
- 定量冷冻喷雾未显著降低6个月杯状细胞密度。
- 治疗6个月圣乔治呼吸问卷总分改善-9.6分(SD 11.1;p=0.022)。
- 治疗6个月呼气低衰减区(-856 HU)减少8.6%(SD 4.6;p<0.0001)。
核心结论
- 定量冷冻喷雾未降低慢性支气管炎患者6个月杯状细胞密度,但改善症状负担和影像学气体陷闭指标,显示安全有效潜力。
研究设计与样本
- 1:1随机、盲法、假手术对照的机制性试验,纳入慢阻肺合并慢性支气管炎患者,定量冷冻喷雾组15例治疗、14例完成随访,假手术组17例完成治疗和随访,均接受标准临床治疗。
主要发现
- 意向性分析中,定量冷冻喷雾组6个月杯状细胞密度较假手术组变化为60.7细胞/mm基底膜(CI -49.3至170.8;p=0.49),未显著降低。
- 定量冷冻喷雾组6个月圣乔治呼吸问卷总分较假手术组改善-9.6分(SD 11.1;p=0.022)。
- 定量冷冻喷雾组6个月呼气低衰减区(-856 Hounsfield单位)较假手术组减少8.6%(SD 4.6;p<0.0001)。
- 假手术组2例患者报告3例次非器械相关严重不良事件。
临床怎么用
- 定量冷冻喷雾可能作为慢性支气管炎改善症状和气体陷闭的候选治疗,但杯状细胞密度未降低,需进一步验证。
局限性
- 样本量小(冷冻喷雾组15例治疗、14例完成随访;假手术组17例完成),为机制性试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with chronic bronchitis suffer high morbidity and rapid functional decline; thus, novel treatments are needed. Metered cryospray delivers titrated applications of liquid nitrogen to the bronchial tree via bronchoscopy, with between-group efficacy and the mechanism of treatment action unknown. METHODS: A 1:1 randomised, blinded, sham-controlled, mechanistic trial of metered cryospray in patients with chronic obstructive pulmonary disease and chronic bronchitis, who receive metered cryospray (n=15 treated, n=14 completed follow-up) or sham-bronchoscopy (n=17 completed treatment and follow-up), in addition to standard clinical care. The primary outcome measure was the between group difference in change in mean goblet cell density per mm of epithelial basement membrane in endobronchial cryobiopsy samples at 6 months relative to baseline. RESULTS: Mean age was 69.2 (SD 8.7) years with 16 (50%) females. In the intention-to-treat analysis, metered cryospray did not reduce goblet cell density (60.7 cells CI -49.3 to 170.8 per mm basement membrane; p=0.49) at 6 months relative to sham-control. Improvement in St George's Respiratory Questionnaire total score was observed with metered cryospray at 6 months (-9.6 points SD 11.1; p=0.022), compared with sham-control. A reduction in expiratory low attenuation area at -856 Hounsfield units was demonstrated with metered cryospray (-8.6% SD 4.6; p<0.0001) at 6 months relative to sham-control. Three serious non-device-related adverse events were reported in two patients in the sham-procedure group. CONCLUSION: In this first randomised sham-controlled study investigating metered cryospray and induced epithelial remodelling as a treatment modality in patients with chronic bronchitis, goblet cell density was not reduced; however, an improvement in symptom burden and radiological air trapping metrics were identified. Metered cryospray demonstrates promise as a safe and efficacious treatment for patients with chronic bronchitis. TRIAL REGISTRATION NUMBER: NCT03892694.
引用
- Orton CM, Tonkin J, Chan LT, et al. Metered cryospray in patients with chronic bronchitis: a mechanistic randomised controlled study. Thorax. 2026. PMID: 42448469. doi:10.1136/thorax-2026-224822
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。